ARCT:NASDAQ, Arcturus Therapeutics Holdings Inc.

ARCT stock overview

Arcturus Therapeutics Holdings Inc. (ARCT:NASDAQ) closed at $8.36 on November 13, 2026, down 0.95% on the day. The stock trades 53.5% below its 52-week high of $17.96 and 52.0% above its 52-week low of $5.50. Over the past year, it gained 15.0%. Arcturus Therapeutics Holdings Inc. is part of the Health Care sector (Major Pharmaceuticals).

Key figures

Price: $8.36
Day change: -0.95%
Volume: 377,105
Average volume: 996,696
Market cap: 240M+
52-week range: $5.50 – $17.96
50-day average: $12.57
200-day average: $9.10

Price action over the past year

In 252 trading sessions since November 13, 2025, ARCT closed higher on 122 days (48%). Its best day was August 19, 2026 (+25.21%) and its worst was November 2, 2026 (-13.96%). The stock moved 10% or more in a single session 12 times. It opened at least 5% above the previous day's high 2 times.

Recent signals

Nov 13, 2026: Down 25.8% over 30 days, from $11.27 (Dips & Crashes scanner)
Nov 13, 2026: Hit a new 1-Month Low of $8.36 (New Highs/Lows scanner)
Nov 5, 2026: News catalyst: Earnings (News Catalysts scanner)
Sep 17, 2026: Spiked to $17.96 on 1M+ shares (Spikes scanner)

ARCT news

Nov 6, 2026: What Arcturus Therapeutics (ARCT) Said on Its Q3 Earnings Call
Nov 5, 2026: Arcturus Beats On A One-Time CSL Windfall, But The Real Story Is A Bigger Pipeline With Later Decision Points
Nov 5, 2026: Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates
Nov 5, 2026: Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress
Nov 4, 2026: Ocugen (OCGN) Reports Q3 Loss, Tops Revenue Estimates
Oct 28, 2026: Arcturus Heads Into Q3 With OTC Data Window Closed And A Rallied Stock Awaiting Proof
Oct 26, 2026: Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026
Oct 23, 2026: Are Medical Stocks Lagging Agilon Health (AGL) This Year?

About Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Ltd is a biotechnology company developing novel RNA medicines. The company develops novel RNA medicines in therapeutic areas including infectious disease, cystic fibrosis, nonalcoholic steatohepatitis (NASH) and rare liver diseases.

Similar stocks

Find more stocks like ARCT with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.